QUANTITATIVE RISK-BENEFIT ANALYSIS OF ORAL PHOSPHODIESTERASE TYPE 5 INHIBITORS ON ERECTILE DYSFUNCTION TREATMENT

被引：0
|
作者：
Hsu, J. C. [1 ]
Tang, D. [2 ]
机构：
[1] Natl Cheng Kung Univ, Taipei, Taiwan
[2] Univ Arizona, Tucson, AZ USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1467
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A283 / A283
页数：1
相关论文
共 50 条
  • [1] Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis
    Hsu, J. C.
    Tang, D. H.
    Lu, C. Y.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 (04) : 436 - 443
  • [2] Drug Insight:: oral phosphodiesterase type 5 inhibitors for erectile dysfunction
    Briganti, A
    Salonia, A
    Gallina, A
    Saccà, A
    Montorsi, P
    Rigatti, P
    Montorsi, F
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (05): : 239 - 247
  • [3] Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction
    Alberto Briganti
    Andrea Salonia
    Andrea Gallina
    Antonino Saccà
    Piero Montorsi
    Patrizio Rigatti
    Francesco Montorsi
    [J]. Nature Clinical Practice Urology, 2005, 2 : 239 - 247
  • [4] Phosphodiesterase type 5 inhibitors for erectile dysfunction
    Carson, CC
    Lue, TF
    [J]. BJU INTERNATIONAL, 2005, 96 (03) : 257 - 280
  • [5] Phosphodiesterase Type 5 Inhibitors and Erectile Dysfunction
    Whittaker, Catherine
    [J]. SA PHARMACEUTICAL JOURNAL, 2009, 76 (05) : 24 - 26
  • [6] Phosphodiesterase type 5 inhibitors and erectile dysfunction
    Whittaker, C.
    [J]. SOUTH AFRICAN FAMILY PRACTICE, 2010, 52 (03) : 207 - 210
  • [7] Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction
    Aversa, Antonio
    Bruzziches, Roberto
    Pili, Marcello
    Spera, Giovanni
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (27) : 3467 - 3484
  • [8] A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction
    Vitezic, D
    [J]. DRUG SAFETY, 2001, 24 (04) : 255 - 265
  • [9] A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction
    Dinko Vitezic
    [J]. Drug Safety, 2001, 24 : 255 - 265
  • [10] A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction
    Hansen, Svenn Alexander
    Aas, Eline
    Solli, Oddvar
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 73 - 84
12345